BB Biotech’s Novavax NVAX Stock Holding History

BB Biotech’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$4.59M	Hold	416,500	–	–	0.12%	34
2018 Q4	$15.3M	Hold	416,500	–	–	0.49%	32
2018 Q3	$15.7M	Hold	416,500	–	–	0.41%	29
2018 Q2	$11.2M	Hold	416,500	–	–	0.32%	31
2018 Q1	$17.5M	Hold	416,500	–	–	0.48%	26
2017 Q4	$10.3M	Hold	416,500	–	–	0.29%	29
2017 Q3	$9.5M	Hold	416,500	–	–	0.26%	26
2017 Q2	$9.58M	Hold	416,500	–	–	0.29%	26
2017 Q1	$10.7M	Hold	416,500	–	–	0.35%	26
2016 Q4	$10.5M	Hold	416,500	–	–	0.39%	26
2016 Q3	$17.3M	Hold	416,500	–	–	0.61%	24
2016 Q2	$60.6M	Hold	416,500	–	–	2.39%	15
2016 Q1	$43M	Hold	416,500	–	–	1.71%	16
2015 Q4	$69.9M	Hold	416,500	–	–	1.97%	14
2015 Q3	$58.9M	Buy	416,500 +7,500	+2%	+$1.68M	1.87%	14
2015 Q2	$91.1M	Sell	409,000 -13,500	-3%	-$2.37M	2.47%	15
2015 Q1	$69.9M	Buy	422,500 +27,500	+7%	+$4.47M	2.08%	18
2014 Q4	$46.8M	Buy	395,000 +20,000	+5%	+$2.09M	1.52%	20
2014 Q3	$31.3M	Buy	+375,000	New	+$33.9M	1.27%	19

Other funds holding NVAX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

BB Biotech's NVAX Position: Q1 2019 in Review

BB Biotech held its Novavax (NVAX) position steady in Q1 2019 at 416,500 shares worth $4.59M. The position accounts for 0.12% of the portfolio, ranked #34.

BB Biotech first reported a position in NVAX in Q3 2014 and has held it in 19 quarters since. The position peaked at $91.1M in Q2 2015. 141 funds tracked by Wall St. Rank hold NVAX as of Q1 2019.

BB Biotech held 416,500 shares of Novavax worth $4.59M as of Q1 2019.
BB Biotech left its Novavax share count unchanged in Q1 2019.
Novavax made up 0.12% of BB Biotech's portfolio in Q1 2019, its #34 holding.
BB Biotech first reported a position in Novavax in Q3 2014 and has held it in 19 quarters since.
BB Biotech's Novavax position peaked at $91.1M in Q2 2015.
141 funds tracked by Wall St. Rank held Novavax as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.